Biomanufacturing

Biologics Manufacturing, Tuesday 19 September 2017

REALISING INDIA'S PHARMA VISION 2020

Organiser’s welcome remarks

Chairman’s opening remarks

Pharma Vision 2020, How close are we to the goal?

The Government of India unveiled 'Pharma Vision 2020' aimed at making India a global leader in end-to-end drug manufacturing. The Indian pharma market is expected to grow to US$ 55 billion by 2020. With the government implementing many new initiatives in its stride toward Pharma Vision 2020, how close are we to achieving it?

India is poised to become a top 5 global pharmaceutical hub by 2020. But in order to achieve this, there’s work to be done, to develop a successful ecosystem. Key stakeholders including the government, pharma, regulators and investors need to work closely together to build it. In this panel, we gather them to explore how, as we explore issues including:

How will the creation of new pharma clusters across India help enhance the ecosystem?

How is the Indian government playing an active role to help build up the ecosystem? (Building infrastructure, funding of incubators and accelerators, mission mode programmes)

Should a robust and sustainable ecosystem be centred around academic institutes to increase collaboration?

What are some existing models which India can emulate? (Boston,SF Bay area, Singapore, BioValley)

Is achieving that too idealistic? How far is India from achieving that?

Conference Day 1 09:30

Boardroom panel: Creating a robust ecosystem for pharma in India

India is poised to become a top 5 global pharmaceutical hub by 2020. But in order to achieve this, there’s work to be done, to develop a successful ecosystem. Key stakeholders including the government, pharma, regulators and investors need to work closely together to build it. In this panel, we gather them to explore how, as we explore issues including:

How will the creation of new pharma clusters across India help enhance the ecosystem?

How is the Indian government playing an active role to help build up the ecosystem? (Building infrastructure, funding of incubators and accelerators, mission mode programmes)

Should a robust and sustainable ecosystem be centred around academic institutes to increase collaboration?

What are some existing models which India can emulate? (Boston,SF Bay area, Singapore, BioValley)

Is achieving that too idealistic? How far is India from achieving that?

Networking Drinks Reception

Biologics Manufacturing, Wednesday 20 September 2017

09:00

Chair’s opening remarks

Looking to the Future

09:10

An organised approach to promoting nation-wide innovation

When it comes to encouraging innovation centers in India, the government has a more decentralised approach where states have the flexibility and funds to build individual programs and innovation centers to promote the growth of biotech hubs. However, sometimes too many cooks may end up spoiling the broth. So how do different government units truly measure the real return of investment of these expenditures, and how do stakeholders work together in organising a more united approach to instilling real innovation within India?

Is the future of medicine personalised?

With the recent advancements in the study of genomics, much progress has been made creating medicines tailored specifically to an individual’s conditions and symptoms. Are we entering a new era of medicine with personalized medicine? To what extent are payers, providers, systems, physicians and patients ready for the change? How will digital technologies and solutions play into the vision of personalised medicine? What are the remaining challenges in making the vision of personalised medicine a reality?

Creating the workforce of the future: A case study on Biocon Academy

Biotechnology is a relatively young field in India, and it can sometimes be challenging to source for helpful manpower as real talented young individuals often get allured by overseas opportunities. This case study will share Biocon’s success story in building an academy with financial support and assistance to help young graduates to explore more options in their career, whilst growing essential talents to support the local ecosystem in India.

Networking Lunch & Exhibition Visit

Chair’s opening remarks

Quality & Compliance

Countries across the globe are concerned about the safety and efficacy of the drugs supplied. As India expands its biologics supply globally, there is an increased emphasis in ensuring uniformity in inspection requirements for drugs manufactured in India. This panel discusses how global regulators such as US FDA, EMA can work closer together with CDSCO in ensuring uniformity in GMP inspections.

Overview of India’s inspection landscape and updates

Understanding the differences and overlaps in current standards

Exploring ways for various regulators to work closer together, including more combined inspections for newly recruited CDSCO inspectors

Conference Day 2 13:30, Biologics Manufacturing

Ensuring uniformity of GMP inspections in biologics manufacturing

Countries across the globe are concerned about the safety and efficacy of the drugs supplied. As India expands its biologics supply globally, there is an increased emphasis in ensuring uniformity in inspection requirements for drugs manufactured in India. This panel discusses how global regulators such as US FDA, EMA can work closer together with CDSCO in ensuring uniformity in GMP inspections.

Overview of India’s inspection landscape and updates

Understanding the differences and overlaps in current standards

Exploring ways for various regulators to work closer together, including more combined inspections for newly recruited CDSCO inspectors